Biotech Values

[DewDiligence]

> MNTA – Good to see you posting positive news about Momenta. I was not sure how to take your previous posts lol<

People sometimes misinterpret my bluntness about a company for dislike (e.g. ThomasS vis-à-vis ANDS). I’ve never disliked MNTA, but I do think a lot of things have to go right for them to realize value for shareholders in the next few years.

The biggest worry is that SNY might cut a deal with TEVA and Amphastar on the Lovenox patent case, thereby leaving MNTA in the lurch on their generic application. Then, by the time MNTA could get its generic Lovenox on the market, newer and better anticoagulants may have taken a significant portion of the Lovenox market. This is one reason I’m not a buyer at the current share price, even after the precipitous decline. Regards, Dew